BACKGROUND: Activation of the mammalian phosphatidylinositol 3-kinase complex can play a critical role in transducing growth factor responses. The lipid kinase complex, which is made up of p85 alpha and p110 alpha regulatory and catalytic subunits, becomes associated with a number of activated receptor protein tyrosine kinases, but the mechanism of its activation has not yet been defined. Recent evidence indicates that Ras can bind to the p85 alpha/p110 alpha complex. We describe here the functional regulation of the mammalian phosphatidylinositol 3-kinase complex by Ras. RESULTS: Expression of p110 alpha, the catalytic subunit of phosphatidylinositol 3-kinase, in the fission yeast, Schizosaccharomyces pombe, has been used to demonstrate an inhibitory effect of p85 alpha on p110 alpha activity in intact cells; inhibition did not result from a decrease in p110 alpha expression. In this cellular context, we have investigated the effect of a constitutively active mutant of Ras, v-Ras, either on p85 alpha or p110 alpha-alone, or on the p85 alpha/p110 alpha complex. In the presence of the p85 alpha/p110 alpha complex, v-Ras suppressed cell growth, but an effector-domain mutant of v-Ras did not. The growth-suppressive effect of v-Ras was not seen for any other combination of expressed proteins. The phenotype induced by v-Ras was consistent with activation of the p85 alpha/p110 alpha complex: it was sensitive to the phosphatidylinositol 3-kinase inhibitor, wortmannin, and the cells accumulated 3-phosphorylated polyphosphoinositides. Activation of purified p85 alpha/p110 alpha by purified recombinant Ras in vitro was also demonstrated. CONCLUSIONS: The phosphatidylinositol 3-kinase complex, p85 alpha/p110 alpha, shows a suppressed catalytic function in vivo when compared with free p110 alpha. This complex can, however, be activated by Ras. We suggest that the phosphatidylinositol 3-kinase p85 alpha/p110 alpha complex is a downstream effector of Ras.
BACKGROUND: Activation of the mammalian phosphatidylinositol 3-kinase complex can play a critical role in transducing growth factor responses. The lipid kinase complex, which is made up of p85 alpha and p110 alpha regulatory and catalytic subunits, becomes associated with a number of activated receptor protein tyrosine kinases, but the mechanism of its activation has not yet been defined. Recent evidence indicates that Ras can bind to the p85 alpha/p110 alpha complex. We describe here the functional regulation of the mammalian phosphatidylinositol 3-kinase complex by Ras. RESULTS: Expression of p110 alpha, the catalytic subunit of phosphatidylinositol 3-kinase, in the fission yeast, Schizosaccharomyces pombe, has been used to demonstrate an inhibitory effect of p85 alpha on p110 alpha activity in intact cells; inhibition did not result from a decrease in p110 alpha expression. In this cellular context, we have investigated the effect of a constitutively active mutant of Ras, v-Ras, either on p85 alpha or p110 alpha-alone, or on the p85 alpha/p110 alpha complex. In the presence of the p85 alpha/p110 alpha complex, v-Ras suppressed cell growth, but an effector-domain mutant of v-Ras did not. The growth-suppressive effect of v-Ras was not seen for any other combination of expressed proteins. The phenotype induced by v-Ras was consistent with activation of the p85 alpha/p110 alpha complex: it was sensitive to the phosphatidylinositol 3-kinase inhibitor, wortmannin, and the cells accumulated 3-phosphorylated polyphosphoinositides. Activation of purified p85 alpha/p110 alpha by purified recombinant Ras in vitro was also demonstrated. CONCLUSIONS: The phosphatidylinositol 3-kinase complex, p85 alpha/p110 alpha, shows a suppressed catalytic function in vivo when compared with free p110 alpha. This complex can, however, be activated by Ras. We suggest that the phosphatidylinositol 3-kinase p85 alpha/p110 alpha complex is a downstream effector of Ras.
Authors: Haiyan Wu; S Chandra Shekar; Rory J Flinn; Mirvat El-Sibai; Bijay S Jaiswal; K Ilker Sen; Vasantharajan Janakiraman; Somasekar Seshagiri; Gary J Gerfen; Mark E Girvin; Jonathan M Backer Journal: Proc Natl Acad Sci U S A Date: 2009-11-13 Impact factor: 11.205
Authors: J B Pracyk; K Tanaka; D D Hegland; K S Kim; R Sethi; I I Rovira; D R Blazina; L Lee; J T Bruder; I Kovesdi; P J Goldshmidt-Clermont; K Irani; T Finkel Journal: J Clin Invest Date: 1998-09-01 Impact factor: 14.808
Authors: C Jimenez; D R Jones; P Rodríguez-Viciana; A Gonzalez-García; E Leonardo; S Wennström; C von Kobbe; J L Toran; L R-Borlado; V Calvo; S G Copin; J P Albar; M L Gaspar; E Diez; M A Marcos; J Downward; C Martinez-A; I Mérida; A C Carrera Journal: EMBO J Date: 1998-02-02 Impact factor: 11.598
Authors: Christina Kiel; Daniel Filchtinski; Michael Spoerner; Gideon Schreiber; Hans Robert Kalbitzer; Christian Herrmann Journal: J Biol Chem Date: 2009-09-23 Impact factor: 5.157
Authors: Bijay S Jaiswal; Vasantharajan Janakiraman; Noelyn M Kljavin; Subhra Chaudhuri; Howard M Stern; Weiru Wang; Zhengyan Kan; Hashem A Dbouk; Brock A Peters; Paul Waring; Trisha Dela Vega; Denise M Kenski; Krista K Bowman; Maria Lorenzo; Hong Li; Jiansheng Wu; Zora Modrusan; Jeremy Stinson; Michael Eby; Peng Yue; Josh S Kaminker; Frederic J de Sauvage; Jonathan M Backer; Somasekar Seshagiri Journal: Cancer Cell Date: 2009-12-08 Impact factor: 31.743
Authors: Frank Schönleben; Wanglong Qiu; Helen E Remotti; Werner Hohenberger; Gloria H Su Journal: Langenbecks Arch Surg Date: 2008-02-21 Impact factor: 3.445